| VAT | 1) Ventricular Activation Time 2) Video-Assisted Thoracoscopy |
|---|---|
| ADR | activation, depression, repetition [in bone remodeling]; adrenodoxin reductase; Adriamycin; adverse ... |
| AE | above-elbow [amputation]; acrodermatitis enteropathica; activation energy; adult erythrocyte; advers... |
| ARAM | antigen recognition activation motif |
| CMNA | complement-mediated neutrophil activation |
simplex (단순
| EEG activation | The low voltage, fast pattern of attentive wakefulness. (05 Mar 2000) |
|---|---|
| trans-activation (genetics) | Increased rate of gene expression directed by either viral or cellular proteins. These regulatory factors (diffusible gene products) act in trans -- that is, act on homologous or heterologous molecules of DNA. (cis-acting factors act only on homologous molecules.) (12 Dec 1998) |
| energy of activation | Energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction; usually expressed in the Arrhenius equation relating a rate constant to absolute temperature. (05 Mar 2000) |
| enzyme activation | Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1) activation by ions (activators); 2) activation by cofactors (coenzymes); and 3) conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. (12 Dec 1998) |
| juxtacrine activation | Activation of target cells by membrane anchored growth factors, also used for activation of leucocytes by PAF bound to endothelial cell surface. (18 Nov 1997) |
| feedback activation | The activation of an enzyme by an end product of a biochemical pathway in which that enzyme plays a part. For example, the activation of factors VIII and V by thrombin during blood clotting. (05 Mar 2000) |
| feed-forward activation | The activation of an enzyme by a precursor of the substrate of that enzyme. (05 Mar 2000) |
| upstream activation site | A DNA sequence that regulates transcription like an enhancer but does notwork if its located downstream from a promoter. (09 Oct 1997) |
| low-activation materials | <radiobiology> In fission reactors, one is forced to deal with the radioactive byproducts of the fission process, but in fusion reactors one generally has a choice of what materials to expose to neutrons produced by the fusion process. A major problem for fusion reactors is developing materials (such as for the reactor vacuum vessel structure) which can be exposed to high levels of neutron bombardment without becoming permanently radioactive. Candidate structural materials which have relatively low induced radiactivation (generally relative to stainless steel) are known as low-activation materials, these include titanium, vanadium, and silicon-carbide. (09 Oct 1997) |
| lymphocyte activation | <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term. (18 Nov 1997) |
| alpha-aminoacyl-peptide hydrolases | <enzyme> Registry number: EC 3.4.11. (12 Dec 1998) |
| anionic neutrophil activating peptide | <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes. It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4. Acronym: IL-8 (12 Dec 1998) |
| antibiotics, peptide | Antibiotics whose structure contains one or more peptides, usually cyclic. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls. (12 Dec 1998) |
| atrial natriuretic peptide | <hormone> This cardiac hormone (28 amino acid residues) regulates salt and water balance in body fluids and blood pressure, it has potential as a medication to treat heart and kidney failure and the buildup of excess fluid in tissue. (09 Oct 1997) |
| bradykinin-potentiating peptide | <chemical> 2-l-tryptophan-3-de-l-leucine-4-de-l-proline-8-l-glutamine bradykinin potentiator b. A synthetic nonapeptide with the sequence pyr-trp-pro-arg-pro-gln-ile-pro-pro, which is identical to that of the peptide from the venom of the snake, bothrops jararaca. It acts as an inhibitor of kininase II and angiotensin I and has been proposed as an antihypertensive agent. Pharmacological action: angiotensin-converting enzyme inhibitors, antihypertensive agents. Chemical name: Bradykinin potentiator B, 2-L-tryptophan-3-de-L-leucine-4-de-L-proline-8-L-glutamine- (12 Dec 1998) |